Swiss pharmaceutical giant Novartis has recently been on the receiving end of two significant enforcement actions: the first for violations of the Foreign Corrupt Practices Act; the second for violations of the False Claims Act and Anti-Kickback Statute.
Tom Fox details the bribery schemes and the internal control failures, outlines just how much Novartis has lost as a result and offers key takeaways for compliance practitioners.
Download the whitepaper below.
[vc_single_image image="37126" img_size="full" css=".vc_custom_1635283872312{margin-top: 50px...
Workplace technology provider Vault's first-ever "Trust Gap Report" has determined that despite a renewed awareness of and interest in preventing...
The Justice Department's probe into the generic pharmaceutical industry has resulted in three new settlements. Each arose from deferred prosecution...
Cyber insurer Allianz Global Corporate & Specialty (AGCS) analyzes risk developments around ransomware in its report, Ransomware Trends: Risk and...
